BioAge Labs Inc. (BIOA)
NASDAQ: BIOAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BIOA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $196.67M
- EPS (TTM)
- -$2.56
- Dividend yield
- None
- 52-week range
- 4.24 – 25.96
- Day range
- 4.24 – 4.77
- Volume / Avg
- 632.10K / 740.06K
- Beta
- —
- Shares outstanding
- 45.95M
52-week range
BIOA stock today
Shares of BioAge Labs (BIOA) finished lower on Nov 20 at $4.28, a drop of 9.13% or $0.43 per share, versus the S&P 500's 3.70% decline. Shares are 83.5% below their 52-week high of $25.96, set on Jul 6, 2026 and 1.1% above the 52-week low of $4.24, near the bottom of the past year's range. BIOA is down 67.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.5%.
BioAge Labs has posted a net loss over the last twelve months (EPS of -$2.56), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BioAge Labs
Company profileBioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Kristen Fortney Ph.D.
- Headquarters
- EmeryVille, CA
- Employees
- 60
- IPO year
- 2024
- Website
- bioagelabs.com
Financial highlights
Full financialsIn fiscal 2025, BioAge Labs generated $9.0 million in revenue, up 0.0% from fiscal 2024. BioAge Labs reported a net loss of $80.6 million, compared with a loss of $71.1 million a year earlier. Operating margin was -1031.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $8.99M | $0 | — |
| Growth | — | — | — |
| Net income | $-80.61M | $-71.11M | $-63.85M |
| EPS (diluted) | $-2.24 | $-6.63 | $-38.17 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$28.78+572.43%
- Strong buy 2
- Buy 5
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.73 vs $-0.68
- Surprise
- -7.35%
BIOA news
All BIOA newsBioAge Labs peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| YARWYarrow Bioscience Inc. | 12.90 | -9.35% | $196.53M | vs BIOA |
| NGENNervGen Pharma Corp. | 1.85 | -3.91% | $198.55M | vs BIOA |
| ACIUAC Immune SA | 1.95 | -8.45% | $193.88M | vs BIOA |
| ANTXAN2 Therapeutics Inc. | 5.08 | -2.68% | $192.75M | vs BIOA |
| DRUGBright Minds Biosciences Inc. | 20.40 | -1.45% | $201.23M | vs BIOA |
| BCYCBicycle Therapeutics plc ADR | 2.90 | -4.92% | $203.27M | vs BIOA |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs BIOA |
| RNACCartesian Therapeutics Inc. | 6.14 | +4.24% | $187.29M | vs BIOA |
Indexes, lists and sector
BioAge Labs stock FAQ
What is BioAge Labs's stock price today?
BIOA last traded at $4.28 as of Nov 20, 4:00 PM EST, down 9.13% on the day. Prices are delayed at least 15 minutes.
Who is BioAge Labs's CEO?
Dr. Kristen Fortney Ph.D. is the chief executive officer of BioAge Labs Inc., which has about 60 employees.
What is the BIOA 52-week high?
The 52-week high for BIOA is $25.96 and the 52-week low is $4.24. The stock is currently 83.5% below its high.